A Phase 3 interventional study of Pantoprazole in Gastroesophageal Reflux Disease (GERD), sponsored by Takeda. Completed at 186 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-07.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks. The study will provide further data on safety and tolerability of pantoprazole.
1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 72 across 712 interventional studies indexed under Gastroesophageal Reflux.
Browse Gastroesophageal Reflux studies →Takeda is the lead sponsor of 1,002 studies on the registry; 92 are open to participants now.
Of its 173 completed or terminated interventional studies of FDA-regulated products, 149 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Pantoprazole 40 mg o.d.
Response to treatment with pantoprazole at week 8, as measured by the questionnaire ReQuest™
Time frame: 8 weeks
Response to treatment with pantoprazole at week 4, as measured by the questionnaire ReQuest™
Time frame: 4 and 8 weeks
Investigator assessment
Time frame: 4 and 8 weeks
Safety and efficacy
Time frame: 4 and 8 weeks
Showing the first 100 of 186 sites across 22 countries.
This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Takeda